Articles Vol. 62 No. 7 (2021) 09/12/2021

CHARACTERISTICS OF NEPHROTOXICITY IN PATIENTS USING VANCOMYCIN

Tran Thi Ly1,2, Le Quang Thanh3,4, Do Van Mai5,6, Bui Dang Phuong Chi7,8
1 Tan Thanh Medical Center
2 Trung tâm Y tế Huyện Tân Thạnh, tỉnh Long An
3 Tu Du Hospital
4 Bệnh viện Từ Dũ
5 Tay Do University
6 3Trường Đại học Tây Đô
7 University of Medicine Pham Ngoc Thach
8 Trường Đại học Y khoa Phạm Ngọc Thạch
Corresponding author: quangthanhbvtd@yahoo.com
DOI: 10.52163/yhc.v62i7 (2021).203
16 Views
0 Downloads
Keywords
Vancomycin, nephrotoxicity.
Abstract

Objectives: To describe the nephrotoxicity characteristics in patients using vancomycin at An Giang Obstetrics and Children’s Hospital. Subjects and methods: Retrospective cohort study on 100 medical records of patients treated at An Giang Obstetrics and Children’s Hospital during the period from January 1st, 2020 to December 31st, 2020. Results: The rate of nephrotoxicity in the study was 24.0%. Median time to toxicity onset was 8 days, interquartile range 4-14 days from drug initiation. The rate of occurrence of nephrotoxicity at different levels: risk, damage and failure were 54.2%, 29.2% and 16.6%, respectively. 33.3% of patients who developed nephrotoxicity had reversible toxicity with a median time to toxicity recovery of 5.2 (3.2 - 14.8) days after the end of dosing. Conclusion: The rate of nephrotoxicity in the study was 24.0%. The rate of occurrence of nephrotoxicity at different levels: risk, damage and failure were 54.2%, 29.2% and 16.6%, respectively. 33.3% of patients with nephrotoxicity had reversible toxicity.

References
[1]
Stefano C, Maya H, Hakim K et al., New Rcgimen for Continuous Infusion of Vancomycin in Critically 111 Patients, Antimicrob Agenís Chemother, 2016; 60(8): 4750-6. Google Scholar
[2]
Davey P, Wilcox MH, Antimicrobial Chemotherapy, 7th edition. Oxtord Univcrsity Press, USA, 2015. Google Scholar
[3]
Timothy H, Tony W, Jeffrey L et al., Vancomycin-associated nephrotoxicity: A meta-analysis of administration by continuous vcrsus intcrmittcnt infusion, lnt J Antimicrob Agents, 2015; 46(3): 249-53. Google Scholar
[4]
Yong PC, Song MM, Kyung MB et al., Treatment Duration for Uncomplicated Staphylococcus aureus Bacteremia To Prevent Relapse: Analysis of a Prospective Observational Cohort Study, Antimicrobial Agents and Chemotherapy, 2013; 57(3): 1150–1156. Google Scholar
[5]
Christopher PK, Grant SF, Kristina ER et al., Comparative prognostic accuracy of sepsis scores for hospital mortality in adults with suspected infection in non-ICU and ICU at an academic public hospital, Plos one, 2019; 1-16. Google Scholar
[6]
Levita KH, Donald IH, Ryan Q et al., High-Dose Vancomycin Therapy for Methicillin-Resistant Staphylococcus aureus Infections, Efficacy and Toxicity, Arch Intern Med, 2006; 166: 2138-2144. Google Scholar
[7]
Pan K, Chen C, Chen Z et al., Vancomycin Associated Acute Kidney Injury: A Longitudinal Study in China, Frontiers in Pharmacology, 2021; 12: 1-9. Google Scholar
[8]
Shigehiko U, Louise C, Hiroshi M et al., Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution, Intensive Care Med, 2002; 28: 1664–1667. Google Scholar